![]() Grant also spent six years at pharmaceutical giant Genentech, where she worked on a pancreatic-cancer drug and learned the ropes of the federal drug-approval process. Since then, she's nabbed degrees in science and business from Stanford, Cambridge, and Yale. Julie Grant got her start in the life sciences during her freshman year in college while interning in a professor's organic chemistry lab. Pact will announce a new CEO later this year. Byers has raised over $125 million for the company while serving as interim CEO. He also helped incubate a new cell-therapy company, Pact Pharma, which is working on technology that reprograms a cancer patient's immune system cells to attack the disease. His research spanned biomedical engineering, stem cells, Parkinson's disease modeling, and more, resulting in multiple journal papers and patents.īyers continued running research projects throughout his academic training and his early years working at GV (formerly Google Ventures).Īs an investor, Byers partners with founders of life science and digital health companies - such as Collective Health, a startup offering tech-savvy tools for managing health benefits, and genetics-testing company 23andMe - to create a global health impact. These are the most interesting and ambitious biotech investors, age 40 and under, on the West Coast:īlake Byers, the son of famed venture capitalist Brook Byers, started doing biomedical research as a high-school student at Stanford University. In addition to the venture capitalists on this list, Business Insider spoke with entrepreneurs and CEOs to gauge the top young biotech stars. "We like to back things that are unlike anything we've ever seen before," said Mohammad Islam, a principal at VC firm DFJ, which recently invested in Memphis Meats - one of the startups aiming to make real meat from animal cells. Some of the biggest recent buzz in the sector has centered on new ways of tackling cancer using patients' own immune systems, fresh therapies built on gene-editing tools like CRISPR, and potentially revolutionary techniques for making meat without factory farming. In January, startup accelerator Y Combinator announced details of its plan to launch a new biotech track focused on advances in the life sciences. But every day some of the sharpest minds in Silicon Valley make big bets on tools and techniques that promise to cure disease, help fix the food system, and even prolong life.īiotech is one of the hottest sectors for venture-capital funds right now. Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. Account icon An icon in the shape of a person's head and shoulders.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |